

Department of Origin: Integrated Healthcare Services	Effective Date: 07/29/22
Approved by: Chief Medical Officer	Date Approved: 07/15/22
Clinical Policy Document: Special Coverage for the COVID-19 Pandemic	Replaces Effective Clinical Policy Dated: 06/01/22
Reference #: MP/C016	Page: 1 of 13

PURPOSE:

The intent of this clinical policy is to provide coverage for benefits available related to the COVID-19 Pandemic.

Unless otherwise stated, this policy is in effect for the duration of the emergency period as declared by the U.S. Secretary of Health and Human Services on January 31, 2020 due to the national public health emergency resulting from the 2019 novel coronavirus. This emergency period began on January 27, 2020 and continues as long as it is continuously extended by the HHS secretary.

POLICY:

Aspirus Health Plan waives cost sharing for all groups for the following services, when received from participating and non-participating providers, for the duration of the emergency period as declared by the U.S. Secretary of Health and Human Services

- Centers for Disease Control (CDC) recommended and FDA-approved testing for the detection of SARS-CoV-2 or the diagnosis of the virus that causes COVID-19; and
- The related office, urgent care, emergency room or telehealth visit which resulted in COVID-19 testing, but only to the extent that such visit is related to the evaluation for and administration of COVID-19 testing; and
- Additional items or services furnished to the member during a visit that results in an order for, or administration of, a COVID-19 test, but only to the extent that the item or service relates to the furnishing or administration of the test or to the evaluation of the member for purposes of determining the need of the member for the product. Examples include testing such as CBC, influenza or strep testing.
- FDA-approved or emergency use authorization (EUA) Coronavirus (COVID-19) vaccination and administration

Aspirus Health Plan waives cost sharing for fully-insured plans for the following services, when received from participating providers

- Administration of an FDA-approved or emergency use authorization (EUA) outpatient monoclonal antibody for COVID infection for the duration of the emergency period as declared by the U.S. Secretary of Health and Human Services (the monoclonal antibody drug is covered by the manufacturer)

Unless otherwise stated, this policy is intended to comply with the Families First Coronavirus Response Act (FFCRA) (H.R. 6201) and applies to all individual and group health plans.

Benefits must be available for health care services. Health care services must be medically necessary, applicable conservative treatments must have been tried, and the most cost-effective alternative must be requested for coverage consideration.

EXCLUSIONS (not limited to):

Refer to member's Certificate of Coverage or Summary Plan Description

CPT 99072 Additional supplies, materials, and clinical staff time over and above those usually included in an office visit or other non-facility service(s), when performed during a Public Health Emergency as defined by law, due to respiratory-transmitted infectious disease is not covered.

Department of Origin: Integrated Healthcare Services	Effective Date: 07/29/22
Approved by: Chief Medical Officer	Date Approved: 07/15/22
Clinical Policy Document: Special Coverage for the COVID-19 Pandemic	Replaces Effective Clinical Policy Dated: 06/01/22
Reference #: MP/C016	Page: 2 of 13

HCPCS S8301 Infection control supplies, not otherwise specified

CODING:

CPT® or HCPCS

COVID-19 Testing

86328 Immunoassay for infectious agent antibody(ies), qualitative or semiquantitative, single step method (eg, reagent strip); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19])

86408 Neutralizing antibody, severe acute respiratory syndrome coronavirus 2(SARS-CoV-2) (Coronavirus disease [COVID-19]); screen

86409 Neutralizing antibody, severe acute respiratory syndrome coronavirus 2(SARS-CoV-2) (Coronavirus disease [COVID-19]); titer

86413 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-10]) antibody, quantitative

86769 Antibody; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19])

87426 Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative, multiple-step method; severe acute respiratory syndrome coronavirus (eg, SARS-CoV, SARS-CoV-2 [COVID-19])

87428 Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative; severe acute respiratory syndrome coronavirus (eg, SARS-CoV, SARS-CoV-2 [COVID-19]) and influenza virus types A and B

87635 Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique

87636 Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) and influenza virus types A and B, multiplex amplified probe technique

87637 Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), influenza virus types A and B, and respiratory syncytial virus, multiplex amplified probe technique

87811 Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19])

0202U Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected.

Department of Origin: Integrated Healthcare Services	Effective Date: 07/29/22
Approved by: Chief Medical Officer	Date Approved: 07/15/22
Clinical Policy Document: Special Coverage for the COVID-19 Pandemic	Replaces Effective Clinical Policy Dated: 06/01/22
Reference #: MP/C016	Page: 3 of 13

0223U Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected

0224U Antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), includes titer(s), when performed

0225U Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 21 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), amplified probe technique, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected

0240U Infectious disease (viral respiratory tract infection), pathogen-specific RNA, 3 targets (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], influenza A, influenza B), upper respiratory specimen, each pathogen reported as detected or not detected

0241U Infections disease (viral respiratory tract infection), pathogen-specific RNA, 4 targets (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], influenza A, influenza B, respiratory syncytial virus [RSV]), upper respiratory specimen, each pathogen reported as detected or not detected

C9803 Hospital outpatient clinical visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source

D0606 Molecular testing for a public health related pathogen, including coronavirus

G2023 Specimen collection for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), any specimen source

G2024 Specimen collection for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), from an individual in a skilled nursing facility or by a laboratory on behalf of a home health agency, any source

U0001 Novel Coronavirus Real Time RT-PCR Diagnostic Test Panel

This code is only to be used for the tests developed by the Centers for Disease Control and Prevention (CDC)

U0002 nCoV Coronavirus, SARS-CoV-2/2019-nCoV (COVID-19), any technique, multiple types or subtypes (includes all targets), non-CDC

Reported by laboratories performing non-CDC laboratory tests for SARS-CoV-2/2019-nCoV (COVID-19)

U0003 Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique, making use of high throughput technologies as described by CMS-2020-01-R

U0004 2019-nCoV Coronavirus, SARS-CoV-2/2019-nCoV (COVID-19), any technique, multiple types or subtypes (includes all targets), non-CDC, making use of high throughput technologies as described by CMS-2020-01-R

Department of Origin: Integrated Healthcare Services	Effective Date: 07/29/22
Approved by: Chief Medical Officer	Date Approved: 07/15/22
Clinical Policy Document: Special Coverage for the COVID-19 Pandemic	Replaces Effective Clinical Policy Dated: 06/01/22
Reference #: MP/C016	Page: 4 of 13

+U0005 Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoC-2) (Coronavirus disease [COVID-19]), amplified probe technique, CDC or non-CDC, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection

COVID-19 Monoclonal Antibodies and Administration

Q0240 Injection, casirivimab and imdevimab, 600 mg

Q0243 Injection, casirivimab and imdevimab, 2400 mg

Q0244 Injection, casirivimab and imdevimab, 1200 mg

M0240 Intravenous infusion or subcutaneous injection, casirivimab and imdevimab, includes infusion or injection and post administration monitoring, subsequent repeat doses

M0241 Intravenous infusion or subcutaneous injection, casirivimab and imdevimab, includes infusion or injection and post administration monitoring, in the home or residence. This includes a beneficiary's home that has been made provider-based to the hospital during the COVID-19 public health emergency, subsequent repeat doses

M0243 Intravenous infusion, casirivimab and imdevimab includes infusion and post administration monitoring

M0244 Intravenous infusion, casirivimab and imdevimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the COVID-19 public health emergency

Q0245 Injection, bamlanivimab and etesevimab, 2100 mg

M0245 Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring

M0246 Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the COVID-19 public health emergency

Q0249 Injection, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with COVID-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, 1 mg

M0249 Intravenous infusion, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with COVID-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, includes infusion and post administration monitoring, first dose

M0250 Intravenous infusion, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with COVID-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, includes infusion and post administration monitoring, second dose

Department of Origin: Integrated Healthcare Services	Effective Date: 07/29/22
Approved by: Chief Medical Officer	Date Approved: 07/15/22
Clinical Policy Document: Special Coverage for the COVID-19 Pandemic	Replaces Effective Clinical Policy Dated: 06/01/22
Reference #: MP/C016	Page: 5 of 13

J0248 Injection, remdesivir, 1mg (Veklury)

Q0222 Injection, bebtelovimab, 175mg

M0222 Intravenous injection, bebtelovimab, includes post administration monitoring

M0223 Intravenous injection, bebtelovimab, includes injection and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency

Vaccination and Administration

- Pfizer-BioNTech COVID-19 vaccine and administration
91300 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted, for intramuscular use

91305 Severe acute respiratory syndrome coronavirus 2 (SARSCoV- 2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use

91307 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use

91308 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use

0001A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; first dose

0002A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; second dose

0003A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; third dose

0004A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; booster dose

0051A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose

Department of Origin: Integrated Healthcare Services	Effective Date: 07/29/22
Approved by: Chief Medical Officer	Date Approved: 07/15/22
Clinical Policy Document: Special Coverage for the COVID-19 Pandemic	Replaces Effective Clinical Policy Dated: 06/01/22
Reference #: MP/C016	Page: 6 of 13

0052A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose

0053A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted, tris-sucrose formulation; third dose

0054A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted, tris-sucrose formulation; booster dose

0071A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose

0072A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose

0073A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; third dose

0074A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; booster dose

0081A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose

0082A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose

0083A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; third dose

D1701 Pfizer-BioNTech Covid-19 vaccine administration - first dose SARSCOV2 COVID-19 VAC mRNA 30mcg/0.3mL IM DOSE 1

D1702 Pfizer-BioNTech Covid-19 vaccine administration - second dose SARSCOV2 COVID-19 VAC mRNA 30mcg/0.3mL IM DOSE 2

Department of Origin: Integrated Healthcare Services	Effective Date: 07/29/22
Approved by: Chief Medical Officer	Date Approved: 07/15/22
Clinical Policy Document: Special Coverage for the COVID-19 Pandemic	Replaces Effective Clinical Policy Dated: 06/01/22
Reference #: MP/C016	Page: 7 of 13

- Moderna COVID-19 vaccine and administration

91301 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage, for intramuscular use

91306 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, for intramuscular use

91309 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use

91311 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative-free, 25 mcg/0.25 mL dosage, for intramuscular use

0011A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage; first dose

0012A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage; second dose

0013A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage; third dose

0064A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage; booster dose

0091A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage; first dose

0092A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage; second dose

0093A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage; third dose

0094A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage; booster dose

Department of Origin: Integrated Healthcare Services	Effective Date: 07/29/22
Approved by: Chief Medical Officer	Date Approved: 07/15/22
Clinical Policy Document: Special Coverage for the COVID-19 Pandemic	Replaces Effective Clinical Policy Dated: 06/01/22
Reference #: MP/C016	Page: 8 of 13

0111A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus (SARS-Co-V-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage; first dose

0112A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus (SARS-Co-V-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage; second dose

0113A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus (SARS-Co-V-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage; third dose

D1703 Moderna Covid-19 vaccine administration - first dose SARSCOV2 COVID-19 VAC mRNA 100mcg/0.5mL IM DOSE 1

D1704 Moderna Covid-19 vaccine administration - second dose SARSCOV2 COVID-19 VAC mRNA 100mcg/0.5mL IM DOSE 2

- Janssen COVID-19 vaccine and administration

91303 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10¹⁰ viral particles/0.5mL dosage, for intramuscular use

0031A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10¹⁰ viral particles/0.5mL dosage, single dose

0034A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10¹⁰ viral particles/0.5mL dosage, booster dose

D1707 Janssen Covid-19 vaccine administration SARSCOV2 COVID-19 vac ad26 5x10¹⁰ vp/0.5ml IM single dose
- Novavax COVID-19 vaccine and administration

91304 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL disease, for intramuscular use

0041A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5 mL dosage; first dose

0042A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5 mL dosage; second dose

M0201 Covid-19 vaccine administration inside a patient's home; reported only once per individual home per date of service when only covid-19 vaccine administration is performed at the patient's home

Department of Origin: Integrated Healthcare Services	Effective Date: 07/29/22
Approved by: Chief Medical Officer	Date Approved: 07/15/22
Clinical Policy Document: Special Coverage for the COVID-19 Pandemic	Replaces Effective Clinical Policy Dated: 06/01/22
Reference #: MP/C016	Page: 9 of 13

Other

Q0220 Injection, tixagevimab and cilgavimab (Evusheld) for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), 300 mg

Q0221 Injection, tixagevimab and cilgavimab (Evusheld), 600 MG

M0220 Injection, tixagevimab and cilgavimab, (Evusheld) for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), includes injection and post administration monitoring

M0221 Injection, tixagevimab and cilgavimab, (Evusheld) for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), includes injection and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency

C9507 Fresh frozen plasma, high titer COVID-19 convalescent, frozen within 8 hours of collection, each unit

CPT codes copyright 2022 American Medical Association. All Rights Reserved. CPT is a trademark of the AMA. The AMA assumes no liability for the data contained herein.

ICD-10 Diagnosis Code Descriptions

- G44.201 Tension-type headache, unspecified, intractable
- G44.209 Tension-type headache, unspecified, not intractable
- G44.211 Episodic tension-type headache, intractable
- G44.219 Episodic tension-type headache, not intractable
- G44.59 Other complicated headache syndrome
- G44.83 Primary cough headache
- G44.84 Primary exertional headache
- G44.85 Primary stabbing headache
- G44.89 Other headache syndrome
- G93.3 Postviral fatigue syndrome
- J00 Acute nasopharyngitis [common cold] (acute rhinitis; acute coryza; infective rhinitis; nasopharyngitis, NOS)
- J02.8 Acute pharyngitis due to other specified organisms
- J02.9 Acute pharyngitis, unspecified (pharyngitis, NOS; sore throat, NOS)
- J06.0 Acute laryngopharyngitis

Department of Origin: Integrated Healthcare Services	Effective Date: 07/29/22
Approved by: Chief Medical Officer	Date Approved: 07/15/22
Clinical Policy Document: Special Coverage for the COVID-19 Pandemic	Replaces Effective Clinical Policy Dated: 06/01/22
Reference #: MP/C016	Page: 10 of 13

- J06.9 Acute upper respiratory infection, unspecified
- J12.81 Pneumonia due to SARS-associated coronavirus
- J12.82 Pneumonia due to coronavirus disease
- J12.89 Other viral pneumonia
- J20.8 Acute bronchitis due to other specified organisms
- J22 Unspecified acute lower respiratory infection
- J40 Bronchitis, not specified as acute or chronic
- J80 Acute respiratory distress syndrome
- J96.00 Acute respiratory failure, unspecified whether with hypoxia or hypercapnia
- J96.01 Acute respiratory failure with hypoxia
- J96.02 Acute respiratory failure with hypercapnia
- J98.8 Other specified respiratory disorders
- M35.81 Multisystem inflammatory syndrome
- M35.89 Other specified systemic involvement of connective tissue
- M54.5 Low back pain
- M54.9 Dorsalgia, unspecified (backache, NOS; back pain, NOS)
- M62.81 Muscle weakness (generalized)
- M62.838 Other muscle spasm
- M79.10 Myalgia, unspecified site (myofascial pain syndrome)
- M79.11 Myalgia of mastication muscle
- M79.12 Myalgia of auxiliary muscles, head and neck
- M79.18 Myalgia, other site
- M79.89 Other specified soft tissue disorders (polyalgia)
- M79.9 Soft tissue disorder, unspecified
- P35.8 Other congenital viral diseases
- R05 Cough
- R06.02 Shortness of breath
- R06.09 Other forms of dyspnea
- R06.1 Stridor
- R06.2 Wheezing
- R06.3 Periodic breathing
- R06.4 Hyperventilation
- R06.82 Tachypnea, not elsewhere classified
- R06.89 Other abnormalities of breathing
- R06.9 Unspecified abnormalities of breathing
- R07.0 Pain in throat
- R07.89 Other chest pain
- R09.2 Respiratory arrest

Department of Origin: Integrated Healthcare Services	Effective Date: 07/29/22
Approved by: Chief Medical Officer	Date Approved: 07/15/22
Clinical Policy Document: Special Coverage for the COVID-19 Pandemic	Replaces Effective Clinical Policy Dated: 06/01/22
Reference #: MP/C016	Page: 11 of 13

R09.81 Nasal congestion
R09.82 Postnasal drip
R10.10 Upper abdominal pain, unspecified
R10.11 Right upper quadrant pain
R10.12 Left upper quadrant pain
R10.13 Epigastric pain
R10.30 Lower abdominal pain, unspecified
R10.31 Right lower quadrant pain
R10.32 Left lower quadrant pain
R10.33 Periumbilical pain
R10.84 Generalized abdominal pain
R10.9 Unspecified abdominal pain
R11.0 Nausea
R11.10 Vomiting, unspecified
R11.11 Vomiting without nausea
R11.12 Projectile vomiting
R11.2 Nausea with vomiting, unspecified
R19.7 Diarrhea, unspecified
R19.8 Other specified symptoms and signs involving the digestive system and abdomen
R23.0 Flushing, excessive blushing
R25.2 Cramp and spasm
R43.0 Anosmia
R43.1 Parosmia
R43.2 Parageusia
R43.8 Other disturbances of smell and taste (mixed disturbance of smell and taste)
R43.9 Unspecified disturbances of smell and taste
R50.9 Fever, unspecified
R51 Headache (facial pain NOS)
R52 Pain, unspecified (acute or generalized pain, NOS)
R53.1 Weakness
R53.81 Other malaise (malaise, NOS; debility NOS; general physical deterioration)
R53.83 Other fatigue (fatigue, NOS; lack of energy; lethargy; tiredness)
R61 Generalized hyperhidrosis, excessive sweating, night sweats, secondary hyperhidrosis
R68.83 Chills (without fever)
U07.1 Other coronavirus as the cause of diseases classified elsewhere
U099 Post-COVID-19 condition, unspecified
Z03.818 Encounter for observation for suspected exposure to other biological agents ruled out
Z11.52 Encounter for screening for COVID-19

Department of Origin: Integrated Healthcare Services	Effective Date: 07/29/22
Approved by: Chief Medical Officer	Date Approved: 07/15/22
Clinical Policy Document: Special Coverage for the COVID-19 Pandemic	Replaces Effective Clinical Policy Dated: 06/01/22
Reference #: MP/C016	Page: 12 of 13

- Z11.59 Encounter for screening for other viral diseases
- Z20.822 Contact with and (suspected) exposure to COVID-19
- Z20.828 Contact with and (suspected) exposure to other viral communicable diseases
- Z86.16 Personal history of COVID-19
- Z86.19 Personal history of other infectious and parasitic diseases

General ICD-10-CM Coding Guidelines

- If the provider documents “suspected”, “possible” or “probable” COVID-19, do not assign code U07.1; assign a code(s) explaining the reason for encounter (such as fever, or Z20.828)
- Note: Diagnosis code B34.2, Coronavirus infection, unspecified, would in generally not be appropriate for the COVID-19, because the cases have universally been respiratory in nature, so the site would not be “unspecified”

ICD-10-CM Official Guidelines for Coding and Reporting FY 2021 (October 1, 2020 - September 30, 2021)

The following coding guidance has been developed by CDC and approved by the four organizations that make up the Cooperating Parties: the National Center for Health Statistics, the American Health Information Management Association, the American Hospital Association, and the Centers for Medicare & Medicaid Services.

- J82.89 plus U07.1 = pneumonia confirmed due to COVID-19
- J20.8 plus U07.1 = acute bronchitis confirmed due to COVID-19
- J22 plus U07.1 = COVID-19 documented as being associated with a lower respiratory infection, not otherwise specified (NOS), or an acute respiratory infection, NOS
- J98.8 plus U07.1 = COVID-19 documented as being associated with a respiratory infection, NOS
- J80 plus U07.1 = ARDS (acute respiratory distress syndrome) due to COVID-19
- Z03.818 = concern about a possible exposure to COVID-19, but this ruled out after evaluation
- Z20.828 = actual exposure to someone who is confirmed to have COVID-19

Acute respiratory failure

For acute respiratory failure due to COVID-19, assign code U07.1, and code J96.0-, Acute respiratory failure.

- Z01.84 Encounter for antibody response examination
Encounter for antibody testing

For an encounter for antibody testing that is not being performed to confirm a current COVID-19 infection, nor is a follow-up test after resolution of COVID-19, assign Z01.84, Encounter for antibody response examination.

- Z09 Encounter for follow-up examination after completed treatment for conditions other than malignant neoplasm

Follow-up visits after COVID-19 infection has resolved

For individuals who previously had COVID-19 and are being seen for follow-up evaluation, and COVID-19 test results are negative, assign codes Z09, Encounter for follow-up examination after completed treatment for conditions other than malignant neoplasm, and Z86.19, Personal history of other infectious and parasitic diseases.

- Z38.00- Z38.8 Liveborn infants according to place of birth and type of delivery
COVID-19 Infection in Newborn

For a newborn that tests positive for COVID-19, assign code U07.1, COVID-19, and the appropriate codes for associated manifestation(s) in neonates/newborns in the absence of

Department of Origin: Integrated Healthcare Services	Effective Date: 07/29/22
Approved by: Chief Medical Officer	Date Approved: 07/15/22
Clinical Policy Document: Special Coverage for the COVID-19 Pandemic	Replaces Effective Clinical Policy Dated: 06/01/22
Reference #: MP/C016	Page: 13 of 13

documentation indicating a specific type of transmission. When coding the birth episode in a newborn record, the appropriate code from category Z38, Liveborn infants according to place of birth and type of delivery, should be assigned as the principal diagnosis.

For a newborn that tests positive for COVID-19 and the provider documents the condition was contracted in utero or during the birth process, assign codes P35.8, Other congenital viral diseases, and U07.1, COVID-19.

REFERENCES:

1. Integrated Healthcare Services Process Manual: UR015 Use of Medical Policy and Criteria
2. Clinical Policy: MP/C009 Coverage Determination Guidelines
3. Families First Coronavirus Response Act H.R. 6201. Retrieved from <https://www.congress.gov/bill/116th-congress/house-bill/6201/text>. Accessed 03-03-21.
4. FAQs About Families First Coronavirus Response Act and Coronavirus Aid, Relief, and Economic Security Act Implementation Retrieved from: <https://www.dol.gov/agencies/ebsa/laws-and-regulations/laws/affordable-care-act/for-employers-and-advisers/aca-implementation-faqs> Accessed 01-24-22.
5. ICD-10-CM Official Guidelines for Coding and Reporting FY 2021 (October 1, 2020 - September 30, 2021). Retrieved from: <https://www.cdc.gov/nchs/data/icd/10cmguidelines-FY2021.pdf> Accessed 03-03-21.

DOCUMENT HISTORY:

Created Date: 03/03/21
Reviewed Date: 03/03/22
Revised Date: 03/15/21, 04/20/21, 04/26/21, 08/23/21, 10/26/21, 12/20/21, 02/02/22, 03/01/22, 04/18/22, 05/26/22, 07/07/22